An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions
Cystic Fibrosis
Interventions
DRUG

Placebo Inhalation Solution

Normal Saline Inhalation Solution

DRUG

SPX-101

SPX-101 Inhalation Solution

Trial Locations (25)

T2N 1N4

University of Calgary Heritage Medical Research Center, Calgary

K1H 8L6

Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa, Ottawa

M5B1W8

Saint Michael's Hospital, Toronto

Unknown

Hospices Civils de Lyon (HCL), Pierre-Bénite

Centre Hospitalier Universitaire Brest, Roscoff

CHU de Rouen, Rouen

CHU de Montpellier, Montpellier

CHU de Angers, Angers

Hopital Pasteur, Nice

Assistance Publique-Hôpitaux de Paris Hôpital Cochin, Paris

Istituto Giannina Gaslini Ospedale Pediatrico, Genoa

Hospital de Santa Maria, Lisbon

Belfast Health and Social Care Trust, Belfast

Heart of England NHS Foundation Trust, Birmingham

University Hospitals Bristol NHS Foundation Trust, Bristol

Western General Hospital - NHS Lothian, Edinburgh

Royal Devon and Exeter NHS Foundation Trust, Exeter

NHS Greater Glasgow and Clyde, Glasgow

The Leeds Teaching Hospitals NHS Trust, Leeds

Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool

Barts Health NHS Trust Saint Bartholomews Hospital, London

Royal Brompton and Harefield NHS Foundation Trust, London

University Hospital of South Manchester NHS Foundation Trust, Manchester

Newcastle Upon Tyne Hospitals, Newcastle upon Tyne

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors
lead

Spyryx Biosciences, Inc.

INDUSTRY

NCT03229252 - An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter